硬脂酰辅酶A去饱和酶抑制剂预防α-突触核蛋白小鼠多种帕金森病表型
该研究在表达野生型人α-突触核蛋白(αS)或家族性PD突变(E35K+E46K+E61K,即3K)的小鼠中,从神经退行和运动综合征起始附近开始经饮水给予硬脂酰辅酶A去饱和酶(SCD)抑制剂5b。5b减少了αS过度磷酸化,预防了WT小鼠的步态缺陷和3K小鼠的静息震颤及进行性运动衰退,并增加αS四聚体、减少富含脂质的蛋白酶K抗性聚集体;遗传性删除一个SCD等位基因也有类似获益。
要点
- 口服SCD抑制剂5b可减少αS过度磷酸化并预防PD样运动表型。
- 5b增加αS四聚体并减少蛋白酶K抗性脂质丰富聚集体。
- 遗传删除一个SCD等位基因提供靶点验证,支持SCD作为治疗靶点。
核心结论
- 长期降低脑内SCD活性可在多种PD模型中预防PD样神经病理,口服SCD抑制剂有望治疗人类α-突触核蛋白病。
研究设计与样本
- 研究在非转基因小鼠中确立5b的口服给药与脑活性,随后在表达野生型人αS(WT)或扩增的家族性PD αS突变(E35K+E46K+E61K,即3K)的小鼠中,从黑质和皮质神经退行及3K小鼠强烈PD样运动综合征起始附近开始,经饮水给予5b。
- 比较5b与安慰剂治疗小鼠的运动表型、脑细胞病理和SCD相关脂质变化,并将结果与3K小鼠与SCD1-/-小鼠杂交的效果进行比较。
主要发现
- 5b治疗降低了表达E46K的人神经元、3K神经培养物以及WT和3K αS小鼠中的αS过度磷酸化。
- 5b预防了WT αS小鼠的轻微步态缺陷以及3K αS小鼠的PD样静息震颤和进行性运动衰退。
- 5b增加了αS四聚体并减少了蛋白酶K抗性脂质丰富聚集体。
- 遗传性删除一个SCD等位基因产生了类似获益,提供靶点验证。
临床怎么用
- 该研究提示口服SCD抑制剂可通过降低脑SCD活性、减少αS过度磷酸化和脂质丰富聚集体来改善PD样表型,为人类α-突触核蛋白病提供潜在疾病修饰治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Parkinson disease (PD) has useful symptomatic treatments that do not slow the neurodegenerative process, and no significant disease-modifying treatments are approved. A key therapeutic target in PD is α-synuclein (αS), which is both genetically implicated and accumulates in Lewy bodies rich in vesicles and other lipid membranes. Reestablishing αS homeostasis is a central goal in PD. Based on previous lipidomic analyses, we conducted a mouse trial of a stearoyl-coenzyme A desaturase (SCD) inhibitor ("5b") that prevented αS-positive vesicular inclusions and cytotoxicity in cultured human neurons. METHODS: Oral dosing and brain activity of 5b were established in nontransgenic mice. 5b in drinking water was given to mice expressing wild-type human αS (WT) or an amplified familial PD αS mutation (E35K + E46K + E61K ["3K"]) beginning near the onset of nigral and cortical neurodegeneration and the robust PD-like motor syndrome in 3K. Motor phenotypes, brain cytopathology, and SCD-related lipid changes were quantified in 5b- versus placebo-treated mice. Outcomes were compared to effects of crossing 3K to SCD1-/- mice. RESULTS: 5b treatment reduced αS hyperphosphorylation in E46K-expressing human neurons, in 3K neural cultures, and in both WT and 3K αS mice. 5b prevented subtle gait deficits in WT αS mice and the PD-like resting tremor and progressive motor decline of 3K αS mice. 5b also increased αS tetramers and reduced proteinase K-resistant lipid-rich aggregates. Similar benefits accrued from genetically deleting 1 SCD allele, providing target validation. INTERPRETATION: Prolonged reduction of brain SCD activity prevented PD-like neuropathology in multiple PD models. Thus, an orally available SCD inhibitor potently ameliorates PD phenotypes, positioning this approach to treat human α-synucleinopathies. ANN NEUROL 2021;89:74-90.
引用
- Nuber S, Nam AY, Rajsombath MM, et al. A Stearoyl-Coenzyme A Desaturase Inhibitor Prevents Multiple Parkinson Disease Phenotypes in α-Synuclein Mice. Ann Neurol. 2020. PMID: 32996158. doi:10.1002/ana.25920
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。